Hypofractionated stereotactic radiotherapy for low- and intermediate-risk prostate cancer patients is a safe and convenient treatment in terms of its duration, PSA response, toxicity and patients’ QoL assessment in the short term. This evidence concerns the gene KLK3 and prostate carcinoma.